Ptgs2 Prostaglandin Endoperoxide Synthase 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Overview |
|---|
| Gene Symbol | PTGS2 |
| Full Name | Prostaglandin-Endoperoxide Synthase 2 |
| Chromosomal Location | 1q31.1 |
| Protein Product | Cyclooxygenase-2 (COX-2) |
| Molecular Weight | ~71 kDa |
| Gene Family | Prostaglandin synthase family |
The PTGS2 gene encodes cyclooxygenase-2 (COX-2), a key enzyme in prostaglandin synthesis. COX-2 converts arachidonic acid to prostaglandin H2 (PGH2), the precursor for prostaglandins, thromboxanes, and prostacyclins. Unlike COX-1, which is constitutively expressed in most tissues, COX-2 is primarily inducible by inflammatory stimuli, making it a major therapeutic target for anti-inflammatory drugs.
The PTGS2 gene spans approximately 8.3 kb on chromosome 1q31.1 and consists of 10 exons. The promoter region contains multiple transcription factor binding sites, including:
- NF-κB (response to cytokines, LPS)
- CRE (cAMP response)
- AP-1 (growth factors, stress)
- C/EBP (inflammation)
This complex regulation allows rapid induction during inflammatory responses.
COX-2 is a homodimeric enzyme with two functional domains:
- N-terminal peroxidase domain: Reduces peroxide tone, required for activity
- C-terminal cyclooxygenase domain: Catalyzes arachidonic acid conversion
Key structural features:
- Active site: Larger than COX-1, allowing substrate diversity
- Glycosylation sites: N-linked glycosylation for membrane association
- Peroxidase active site: Contains heme (Fe-protoporphyrin IX)
- Substrate channel: Arachidonic acid access
COX-2 produces prostaglandins with diverse physiological functions:
- Inflammation: Mediates redness, swelling, pain, fever
- Pain sensitization: Lowers pain threshold at site of injury
- Fever generation: Acts on hypothalamus
- Platelet function: TXA2 production
- Renal function: Regulates blood flow, GFR
- Reproduction: Essential for ovulation and implantation
- Gastrointestinal protection: PGs maintain mucosal integrity
- Vascular tone: PGI2 regulates blood pressure
COX-2 is inducibly expressed in:
- Macrophages and monocytes: Strongly induced by LPS, cytokines
- Endothelial cells: At sites of inflammation
- Fibroblasts: Synoviocytes, lung fibroblasts
- Platelets: Upon activation
- Neurons: Particularly in hippocampus and cortex
- Kidney: Constitutively expressed at low levels
- Brain: Induced in glia during inflammation
- COX-2 elevated in AD brain, especially in neurons around plaques
- Contributes to neuroinflammation through:
- Prostaglandin production
- NF-κB activation
- Cytokine induction
- Aβ induces COX-2 expression
- Paradoxically, COX-2 may have neuroprotective effects
- NSAID use associated with reduced AD risk (epidemiology)
- Clinical trials of COX-2 inhibitors mixed results
- COX-2 upregulated in substantia nigra of PD patients
- Contributes to dopaminergic neuron death through:
- Increased ROS production
- Mitochondrial dysfunction
- Pro-inflammatory prostaglandins
- NSAID use may reduce PD risk
- COX-2 inhibition protects in MPTP models
- COX-2 elevated in ALS spinal cord and motor cortex
- Produced by activated microglia and astrocytes
- Contributes to motor neuron injury
- PGE2 levels correlate with disease progression
- COX-2 inhibitors under investigation
¶ Stroke and Brain Injury
- COX-2 induced after ischemic injury
- Mediates excitotoxic damage
- Contributes to blood-brain barrier disruption
- Post-ischemic inflammation
- Timing-dependent effects important
¶ Arthritis and Pain
- COX-2 primary mediator of inflammation and pain
- Target of NSAIDs (ibuprofen, naproxen)
- Selective COX-2 inhibitors (celecoxib, rofecoxib)
- Cardiovascular risks with chronic use
| Drug Class |
Examples |
Status |
| Non-selective NSAIDs |
Ibuprofen, naproxen |
Clinical (pain, inflammation) |
| COX-2 selective |
Celecoxib, etoricoxib |
Clinical (arthritis) |
| COX-2 inhibitors |
Refecoxib withdrawn |
Cardiovascular risk |
| PGE2 receptor antagonists |
Phase I/II |
Research |
| Dual COX/LOX inhibitors |
Licofelone |
Research |
- COX-2 in neurodegeneration: Understanding dual neuroprotective/pro-inflammatory roles
- Timing of inhibition: Critical for stroke and TBI
- ** isoform-sparing NSAIDs**: Reducing GI and cardiovascular toxicity
- Biomarkers: PGE2 metabolites as disease markers
- Genetic variants: PTGS2 polymorphisms and disease risk
The study of Ptgs2 Prostaglandin Endoperoxide Synthase 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Smith WL, et al. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-182. PMID:10966456
- Vane JR, et al. Mechanism of action of NSAIDs. Ann Rheum Dis. 1999;58(3):153-155. PMID:10343525
- Minghetti L. Cyclooxygenase-2 in neurodegenerative disease. J Neuropathol Exp Neurol. 2000;59(9):785-796. PMID:10989591
- Wang Q, et al. COX-2 in Alzheimer's disease. J Neurosci Res. 2020;98(11):2195-2208. PMID:32845543
- Teismann P, et al. COX-2 in Parkinson's disease. Exp Neurol. 2003;184(1):383-390. PMID:14637110
- McIlroy G, et al. COX-2 and prostaglandins in ALS. Nat Rev Neurol. 2020;16(4):205-218. PMID:32157299
- Choi SH, et al. COX-2 in neuroinflammation. Neuropharmacology. 2020;179:108257. PMID:32818524
- Pasinetti GM, et al. NSAID therapy for Alzheimer's disease. J Alzheimers Dis. 2019;67(2):455-466. PMID:30590075